Valneva Tops the SBF 120 After Shigellosis Trial Results
The Lyon-based vaccine maker posts the strongest gain on the index at midday, in a Paris market trading higher. The move follows the publication of clinical data on a candidate against an infectious disease for which no vaccine is currently approved, and extends a rebound under way for several sessions.
Positive Phase 2 Trials for the Shigellosis Vaccine
Valneva gains 4.56% to €2.62, leading the SBF 120 while the index rises 0.38%.
On Monday, the group published the results of two phase 2 trials of S4V2, its tetravalent vaccine candidate against shigellosis, a disease for which no vaccine is currently approved. Valneva says it is evaluating all the data to determine the most appropriate development pathway, without specifying a timeline.
The stock has already recovered 6.65% over one week and 15.45% over three months, but it remains down 28.49% over one year. In Paris, the ordinary share dominates trading by a wide margin, the Nasdaq-listed version being very lightly traded.
Price Back Above Its MM20 and Targeting €2.77
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In terms of price benchmarks, Valneva stands 5.06% above its MM20 at €2.49, but remains 1.65% below its MM50 at €2.66. Resistance at €2.77 becomes the next level to break, with support at €2.33.
Sanofi, another sector stock, rises 2.38% on Monday and shows a gain of 19.87% over one month.
On the agenda, Valneva will participate on November 16 in the Jefferies Global Healthcare Conference, an event where the group had announced its intention to present its value creation drivers, foremost among them its candidate against Lyme disease.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
EBITDA margin: -60,4 %
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
